Fabric Genomics, a global computational genomics company, and Sentieon, which develops highly optimized algorithms for bioinformatics applications, announced a technology partnership that will enhance Fabric Genomics’ secondary analysis capabilities within Fabric Enterprise, the company’s new end-to-end precision medicine platform.
Fabric Genomics’ new secondary analysis offering, Fabric Standard, is 10 times faster than commonly adopted BWA-GATK tools. Unlike BWA-GATK, Fabric Standard has no down-sampling of reads and is deterministic, even when run on multiple threads. This leads to more accurate scientific results and better overall efficiency.
“By adding Sentieon’s award-winning algorithms to Fabric Enterprise, we are able to deliver a seamless end-to-end solution for genomic data analysis, from FASTQ to clinical report,” said Matt Tindall, CEO of Fabric Genomics. “This marks a broad expansion in our capabilities as a company and provides our customers with the option to work with one software partner for all their NGS testing needs.”
Fabric Genomics and Sentieon plan to co-develop new next-generation variant calling capabilities for hereditary disease and oncology, yielding accuracy improvements beyond the tools that are available today. A key focus for the companies will also be developing structural variant and copy number variant capabilities for genomic analysis built upon Sentieon’s ICGC-TCGA Dream Challenge-winning tools and Fabric Genomics’ BioGraph technology.
“Working with Fabric Genomics, Sentieon can help to improve patient care around the world with a best-in-class total solution for clinical care,” remarked Dr. Jun Ye, Sentieon’s CEO. “We anticipate opportunities to build important and powerful new applications with the Fabric Genomics team.”
In January 2017, Fabric Genomics acquired Seattle-based Spiral Genetics, an innovative secondary analysis software company. Spiral’s breakthrough, graph-based technology, BioGraph, is designed to enable population-scale data mining and accurate detection of structural variants for clinical laboratories, life science companies and country sequencing programs.